ADAM HAMMETT: Open Payments
NPI 1881005825 · SPARTANBURG, SC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,775 in 70 payments from 16 companies in 2025. Trend: 2023 $1,219 · 2024 $1,224 · 2025 $3,775
Consulting: $2,095Food & beverage: $1,680
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. | 2 | $1,933 |
| AstraZeneca Pharmaceuticals LP | 13 | $650 |
| Amgen Inc. | 9 | $472 |
| Lilly USA, LLC | 9 | $150 |
| ABBVIE INC. | 16 | $135 |
| Verona Pharma, Inc. | 1 | $86 |
| PFIZER INC. | 4 | $79 |
| Novo Nordisk Inc | 5 | $75 |
| Merck Sharp & Dohme LLC | 3 | $46 |
| GlaxoSmithKline, LLC. | 2 | $35 |
Products named: Biktarvy, AIRSUPRA, OTEZLA, PROLIA, BREZTRI, VRAYLAR, Ohtuvayre, FARXIGA.
Industry payments across SC — which companies pay providers there.
